FLINT, Mich., June 8, 2017 /PRNewswire/ -- Diplomat
Pharmacy, Inc. (NYSE: DPLO), shareholders elected Mr. Park to
its board of directors at today's annual shareholders meeting.
He will serve a three-year term as a Class III director.
Park served as chief operating officer for OptumRx, the pharmacy
care services business of UnitedHealth Group, from July 2015 to July
2016 after OptumRx merged with pharmacy benefit manager
(PBM) Catamaran Corporation. Park had been Catamaran's executive
vice president of operations since March
2014 after becoming chief financial officer in 2006.
Before serving as chief financial officer, Park was a member of
Catamaran's board of directors and a senior vice president of
Covington Capital Corporation, a private equity venture capital
firm, where he was responsible for assessing new business
opportunities, negotiating and structuring transactions and
advising investee companies. He has also worked for IBM in several
areas of its Global Services Organization and as an audit manager
with Deloitte Canada.
Park has held key managerial, financial, and operational
responsibilities during his 11 years in the health care industry,
playing a significant role in acquisitions and organic growth. He
has extensive financial, accounting, and corporate governance
experience.
"Jeff Park is an important
addition to Diplomat's board of directors," said Phil Hagerman, CEO and chairman of Diplomat. "He
has substantial experience in the PBM industry, a field significant
to our business. Our board believes Jeff's broad experience across
important industries will add a valuable perspective to our growth
strategy."
Ben Wolin, Diplomat's independent
lead director, added, "We are enthusiastic about Jeff Park joining as a director and look forward
to benefitting from his judgement, counsel, and unique
expertise.
"I'm honored to begin working more closely with my fellow board
members," Park said. "Diplomat does an incredible job putting the
patients first as the largest independent provider of specialty
pharmacy services. I'm excited to work with a company that has
maintained personal care on a national level."
To learn more about Diplomat, visit diplomat.is.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements give
current expectations or forecasts of future events or our future
financial or operating performance. The forward-looking
statements contained in this press release are based on
management's good-faith belief and reasonable judgment based on
current information. These statements are qualified by
important risks and uncertainties, many of which are beyond our
control, that could cause our actual results to differ materially
from those forecasted or indicated by such forward-looking
statements. For a discussion of such risks and uncertainties, you
should review Diplomat's filings with the Securities and Exchange
Commission, including "Risk Factors" in Diplomat's Annual Report on
Form 10-K for the year ended Dec. 31,
2016, and in subsequent reports filed with or furnished to
the Securities and Exchange Commission. Except as may be
required by any applicable laws, Diplomat assumes no obligation to
publicly update such forward-looking statements, which are made as
of the date hereof or the earlier date specified herein, whether as
a result of new information, future developments or otherwise.
About Diplomat
Diplomat (NYSE: DPLO) is the nation's largest independent
provider of specialty pharmacy services—helping patients and
providers in all 50 states. The company offers medication
management programs for people with complex chronic diseases and
delivers unique solutions for manufacturers, hospitals, payors,
providers, and more. Diplomat opened its doors in 1975 as a
neighborhood pharmacy with one essential tenet: "Take good care of
patients and the rest falls into place." Today, that tradition
continues—always focused on improving patient care and clinical
adherence. For more information, visit diplomat.is.
INVESTOR CONTACT:
Bob
East, Westwicke Partners
443.213.0500 | diplomat@westwicke.com
MEDIA CONTACT:
Jenny
Cretu, Diplomat
810.768.9370 | press@diplomat.is
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/jeff-park-elected-to-diplomat-board-of-directors-300471372.html
SOURCE Diplomat Pharmacy, Inc.